UK markets open in 2 hours 1 minute
  • NIKKEI 225

    27,550.37
    -230.65 (-0.83%)
     
  • HANG SENG

    25,987.16
    -248.64 (-0.95%)
     
  • CRUDE OIL

    71.18
    -0.08 (-0.11%)
     
  • GOLD FUTURES

    1,815.00
    -7.20 (-0.40%)
     
  • DOW

    34,838.16
    -97.31 (-0.28%)
     
  • BTC-GBP

    27,653.02
    -1,081.99 (-3.77%)
     
  • CMC Crypto 200

    934.05
    -26.84 (-2.79%)
     
  • ^IXIC

    14,681.07
    +8.39 (+0.06%)
     
  • ^FTAS

    4,061.12
    +30.88 (+0.77%)
     

Is Cara Therapeutics a Buy?

·4-min read
Is Cara Therapeutics a Buy?

With the clinical trial process in the rearview mirror, a lot of the risks associated with development are in the past, leaving "only" the risks of competing profitably. Such is the situation of Cara Therapeutics (NASDAQ: CARA), which is developing a drug called Korsuva to treat pruritus. You've probably experienced pruritus (at least to a small degree) before, because it's the sensation of itchiness.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting